Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Chem Sci
2017 Mar 01;83:2003-2009. doi: 10.1039/c6sc04854d.
Show Gene links
Show Anatomy links
A resorcinarene for inhibition of Aβ fibrillation.
Han X
,
Park J
,
Wu W
,
Malagon A
,
Wang L
,
Vargas E
,
Wikramanayake A
,
Houk KN
,
Leblanc RM
.
???displayArticle.abstract???
Amyloid-β peptides (Aβ) fibrillation is the hallmark of Alzheimer''s disease (AD). However, it has been challenging to discover potent agents in order to inhibit Aβ fibrillation. Herein, we demonstrated the effect of resorcinarene on inhibiting Aβ fibrillation in vitro via experimental and computational methods. Aβ were incubated with different concentrations of resorcinarene so as to monitor the kinetics by using thioflavin T binding assay. The results, which were further confirmed by far-UV CD spectroscopy and atomic force microscopy, strongly indicated that the higher concentration of resorcinarene, the more effective the inhibition of Aβ fibrillation. A cytotoxicity study showed that when sea urchin embryos were exposed to the resorcinarene, the majority survived due to the resorcinarene low toxicity. In addition, when the resorcinarene was added, the formation of toxic Aβ 42 species was delayed. Computational studies of Aβ fibrillation, including docking simulations and MD simulations, illustrated that the interaction between inhibitor resorcinarene and Aβ is driven by the non-polar interactions. These studies display a novel strategy for the exploration of promising antiamyloiddogenic agents for AD treatments.
Fig. 1. A schematic overview in vitro study of Aβ fibrillation, which includes the conformational transition from monomer to partially folded intermediate or oligomer to mature fibrils.
Scheme 1. The structure of resorcinarene.
Fig. 2. (a) Kinetics of 10 μM of Aβ 42 and Aβ 40 fibrillation: fluorescence intensity of thioflavin T (ThT) at 485 nm as a function of incubation time at 37 °C in 25 mM PBS, pH 7.4 with the ratio of Aβ to 1 at 1â:â0, 1â:â0.1, 1â:â1, and 1â:â5, respectively. The final concentration was a 2-fold dilution with 20 μM ThT. Baseline was corrected against the spectra of 1 (Fig. S2â ). The ThT fluorescence was obtained for three repeats of each sample. The error bars indicate the standard error of the mean. (b) Far-UV circular dichroism spectra of 10 μM Aβ 42 alone (top panel) in 25 mM pH = 7.4 PBS at 0, 12, 48, 72 h, and 10 μM Aβ 42 incubated with 10 μM 1 (bottom panel), in 25 mM pH = 7.4 PBS at 0, 24, 48, 96 h. AFM images (size: 2.5 à 2.5 μm) of 10 μM Aβ 42 incubated at 37 °C in 25 mM PBS, pH 7.4 with (c) 0 μM, (d) 1 μM, and (e) 10 μM 1, respectively.
Fig. 3. (a) Cytotoxicity test of resorcinarene to seaurchin embryos. (b) The inhibitory effect of resorcinarene on the cytotoxicity of Aβ 42 fibrils at different molar ratios of Aβ 42 to resorcinarene.
Fig. 4. Predicted interactions of the resorcinearene and the Aβ 42 amyloid filament. Two of the relatively stable interactions patterns are predicted using the PELE and the MD simulations: (a) and (b). The last snapshots from the MD simulations are illustrated. Root-mean-squared deviations from the initial docked structure (blue), the last configuration of the MD simulation (red), and the buried surface area of the ligandâprotein interface (orange) of each are plotted on bottom.
Arosio,
Quantification of the concentration of Aβ42 propagons during the lag phase by an amyloid chain reaction assay.
2014, Pubmed
Arosio,
Quantification of the concentration of Aβ42 propagons during the lag phase by an amyloid chain reaction assay.
2014,
Pubmed
Arosio,
Chemical kinetics for drug discovery to combat protein aggregation diseases.
2014,
Pubmed
Bian,
Beam pen lithography as a new tool for spatially controlled photochemistry, and its utilization in the synthesis of multivalent glycan arrays.
2014,
Pubmed
Cohen,
A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers.
2015,
Pubmed
Cohen,
Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.
2013,
Pubmed
Cohen,
From macroscopic measurements to microscopic mechanisms of protein aggregation.
2012,
Pubmed
Ebbing,
Resorcinarenes with 2-benzimidazolone bridges: self-aggregation, self-assembled dimeric capsules, and guest encapsulation.
2002,
Pubmed
Eisenberg,
The amyloid state of proteins in human diseases.
2012,
Pubmed
Ferri,
Global prevalence of dementia: a Delphi consensus study.
2005,
Pubmed
Funke,
Peptides for therapy and diagnosis of Alzheimer's disease.
2012,
Pubmed
Gessel,
Aβ(39-42) modulates Aβ oligomerization but not fibril formation.
2012,
Pubmed
Geula,
Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity.
1998,
Pubmed
Goedert,
A century of Alzheimer's disease.
2006,
Pubmed
Habchi,
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
2016,
Pubmed
Han,
Interactions between Carbon Nanomaterials and Biomolecules.
2016,
Pubmed
Han,
Carbohydrate nanotechnology: hierarchical assembly using nature's other information carrying biopolymers.
2015,
Pubmed
Hardy,
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
2002,
Pubmed
Hellstrand,
Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process.
2010,
Pubmed
Jakob-Roetne,
Alzheimer's disease: from pathology to therapeutic approaches.
2009,
Pubmed
Knowles,
The amyloid state and its association with protein misfolding diseases.
2014,
Pubmed
Lansbury,
Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease.
1997,
Pubmed
Lee,
Supramolecular inhibition of amyloid fibrillation by cucurbit[7]uril.
2014,
Pubmed
Madadkar-Sobhani,
PELE web server: atomistic study of biomolecular systems at your fingertips.
2013,
Pubmed
Maier,
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.
2015,
Pubmed
Mansikkamäki,
Noncovalent pi.pi-stacked exo-functional nanotubes: subtle control of resorcinarene self-assembly.
2004,
Pubmed
Mattson,
Pathways towards and away from Alzheimer's disease.
2004,
Pubmed
Mutihac,
Recognition of amino acids by functionalized calixarenes.
2011,
Pubmed
Nicholls,
Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.
1991,
Pubmed
Nie,
Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.
2011,
Pubmed
Peng,
Determination of the composition, encapsulation efficiency and loading capacity in protein drug delivery systems using circular dichroism spectroscopy.
2016,
Pubmed
Rodik,
Calixarenes in bio-medical researches.
2009,
Pubmed
Sanabria,
Synthesis and characterization of two sulfonated resorcinarenes: a new example of a linear array of sodium centers and macrocycles.
2015,
Pubmed
Selkoe,
Translating cell biology into therapeutic advances in Alzheimer's disease.
1999,
Pubmed
Sievers,
Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation.
2011,
Pubmed
Suzuki,
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.
1994,
Pubmed
Teplow,
Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach.
2006,
Pubmed
Tjernberg,
Arrest of beta-amyloid fibril formation by a pentapeptide ligand.
1996,
Pubmed
Walsh,
A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide.
2009,
Pubmed
Wang,
Tanshinones inhibit amyloid aggregation by amyloid-β peptide, disaggregate amyloid fibrils, and protect cultured cells.
2013,
Pubmed
Wang,
Development and testing of a general amber force field.
2004,
Pubmed
Xiong,
Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity.
2015,
Pubmed
Yankner,
Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.
1990,
Pubmed
Zhang,
Nanomaterials for reducing amyloid cytotoxicity.
2013,
Pubmed
Zheng,
Amyloid β-protein assembly: The effect of molecular tweezers CLR01 and CLR03.
2015,
Pubmed